A Phase 1/2 interventional study of Mitomycin C and Chemophase in Bladder Cancer, sponsored by Halozyme Therapeutics. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-29.
Sponsored by Halozyme Therapeutics · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing mitomycin in Urinary Bladder Neoplasms — 5 open to participants now, 10 under way, 2 of them phase 3. Mitomycin · Urinary Bladder Neoplasms.
Among the 26 studies testing mitomycin in Urinary Bladder Neoplasms, this one is the 20th largest by enrollment, is the only one that started in 2006, is one of 2 in phase 1/2, and was the 3rd registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →5 of the 26 studies testing mitomycin in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
National Cancer Center, Korea · Sites in Korea, Republic of
Ages 20+
Hospital Centre Biel/Bienne · Sites in Switzerland
Ages 18+
First Affiliated Hospital of Wenzhou Medical University · Sites in China
Ages 18+
By country, each count listing its studies:
Mitomycin: first FDA approval 1981 (MUTAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 14 · Phase 3 8 · Phase 4 2
First in 2001; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 61 across the 26 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 26 have an industry lead sponsor. The 10 most frequent:
Halozyme Therapeutics is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Halozyme Therapeutics has 1 study filed under Urinary Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing mitomycin in Urinary Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05024734Roland Seiler-BlarerGuiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids | 2026-12-31 |
| NCT07821177Dana-Farber Cancer InstituteBladder Preservation or Cystectomy for MIBC | 2027-09 |
| NCT07189793First Affiliated Hospital of Wenzhou Medical UniversityToripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies testing mitomycin in Urinary Bladder Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to explore a treatment that potentially enhances the delivery of chemotherapy to tumors in participants with superficial bladder cancer. The investigational medication to be studied is an enzyme called ChemophaseTM (recombinant human hyaluronidase, rHuPH20). Chemophase is being specifically developed for use with other anticancer drug to increase the local penetration of the anticancer drug for the treatment of superficial bladder cancer. In this study, Chemophase will be given in combination with mitomycin C directly into the bladder. Mitomycin C is an anti-tumor drug that is commonly used to treat superficial bladder cancer. It is envisioned that Chemophase with mitomycin C may potentially increase the local penetration of mitomycin C into remaining cancer cells following surgery to treat superficial bladder cancer.
The primary objectives of this study are to:
The secondary objectives of this study are to:
Study participants will receive six weekly study treatments administered intravesically (at Weeks 1 through 6) followed by post-treatment evaluations, at Weeks 8 and 12. The 12 participants treated at MTD will continue to receive combination therapy every three months until the end of Year 2 or until the time of documented tumor recurrence, whichever occurs first. For other participants, long-term follow-up after Week 12 will consist of disease monitoring of participants by telephone and will be performed every three months beginning three months after last study treatment for two years and then every six months thereafter, until bladder tumor recurrence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 40 milligrams (mg) MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 20,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
Drug: Mitomycin C · Drug: Chemophase
Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 60,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
Drug: Mitomycin C · Drug: Chemophase
Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 200,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
Drug: Mitomycin C · Drug: Chemophase
Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 400,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
Drug: Mitomycin C · Drug: Chemophase
Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 800,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
Drug: Mitomycin C · Drug: Chemophase
intravesical administration
intravesical administration
Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC
The MTD was defined as the maximum dose level at which no more than two of six participants experienced dose-limiting toxicities (DLT). DLT was defined as any of the following: * Plasma MMC concentration greater than or equal to (\>=) 100 nanograms (ng)/milliliter (mL) * Adverse event (AE) with a Common Toxicity Criteria (CTC) grade greater than or equal to 3 * New, treatment-emergent diagnosis of bladder fibrosis.
Time frame: 5 weeks (Week 2 to Week 6)
Number of Participants With Dose Limiting Toxicities (DLTs)
DLT was defined as any of the following: * Plasma MMC concentration \>= 100 ng/mL * AE with a CTC grade greater than or equal to 3 * New, treatment-emergent diagnosis of bladder fibrosis.
Time frame: 5 weeks (Week 2 to Week 6)
Recommended Dose of Chemophase With MMC For Future Studies
Time frame: 5 weeks (Week 2 to Week 6)
Number of Participants With a Quantifiable MMC Plasma Concentration Value
A quantifiable MMC plasma concentration value was a value that was not below the quantifiable limit (BQL) of \<10.0 nanogram/milliliter (ng/mL).
Time frame: 0 (predose), 1, 2, and 3 hours postdose at Weeks 1, 2, 5, and 6
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
TEAEs were defined as any AE that occurred after the first administration of the study drug and until the end of the study. AEs were defined as any untoward medical occurrence in a participant administered study drug and that did not necessarily have a causal relationship with the study drug. SAEs were defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, an important medical event. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in 'Reported Adverse Events' Section.
Time frame: Baseline up to 2 years
Number of Participants Who Remained Tumor Free at the End of the Study
Time frame: Baseline up to 2 years
| Milestone | Cohort 1: MMC Plus Chemophase 20,000 U | Cohort 2: MMC Plus Chemophase 60,000 U | Cohort 3: MMC Plus Chemophase 200,000 U | Cohort 4: MMC Plus Chemophase 400,000 U | Cohort 5: MMC Plus Chemophase 800,000 U |
|---|---|---|---|---|---|
| Started | 3 | 3 | 6 | 3 | 12 |
| Received at least 1 dose of study drug | 3 | 3 | 6 | 3 | 12 |
| Completed | 3 | 3 | 6 | 3 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Participant's decision | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Investigator's decision | 0 | 0 | 0 | 0 | 1 |
The MTD was defined as the maximum dose level at which no more than two of six participants experienced dose-limiting toxicities (DLT). DLT was defined as any of the following: * Plasma MMC concentration greater than or equal to (\>=) 100 nanograms (ng)/milliliter (mL) * Adverse event (AE) with a Common Toxicity Criteria (CTC) grade greater than or equal to 3 * New, treatment-emergent diagnosis of bladder fibrosis.
| Units | Cohort 5: MMC Plus Chemophase 800,000 U |
|---|---|
| Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC | 800000 |
DLT was defined as any of the following: * Plasma MMC concentration \>= 100 ng/mL * AE with a CTC grade greater than or equal to 3 * New, treatment-emergent diagnosis of bladder fibrosis.
| Participants | Cohort 1: MMC Plus Chemophase 20,000 U | Cohort 2: MMC Plus Chemophase 60,000 U | Cohort 3: MMC Plus Chemophase 200,000 U | Cohort 4: MMC Plus Chemophase 400,000 U | Cohort 5: MMC Plus Chemophase 800,000 U |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 | 1 | 0 | 0 |
| Units | Cohort 5: MMC Plus Chemophase 800,000 U |
|---|---|
| Recommended Dose of Chemophase With MMC For Future Studies | 800000 |
A quantifiable MMC plasma concentration value was a value that was not below the quantifiable limit (BQL) of \<10.0 nanogram/milliliter (ng/mL).
| Participants | Cohort 1: MMC Plus Chemophase 20,000 U | Cohort 2: MMC Plus Chemophase 60,000 U | Cohort 3: MMC Plus Chemophase 200,000 U | Cohort 4: MMC Plus Chemophase 400,000 U | Cohort 5: MMC Plus Chemophase 800,000 U |
|---|---|---|---|---|---|
| Week 1: Predose | 0 | 0 | 0 | 0 | 0 |
| Week 1: 1 hour | 0 | 0 | 0 | 0 | 1 |
| Week 1: 2 hours | 0 | 0 | 0 | 0 | 1 |
| Week 1: 3 hours | 0 | 0 | 0 | 0 | 0 |
| Week 2: Predose | 0 | 0 | 0 | 0 | 0 |
| Week 2: 1 hour | 0 | 0 | 0 | 0 | 0 |
| Week 2: 2 hours | 0 | 0 | 0 | 0 | 0 |
| Week 2: 3 hours | 0 | 0 | 0 | 0 | 0 |
| Week 5: Predose | 0 | 0 | 0 | 0 | 0 |
| Week 5: 1 hour | 0 | 0 | 0 | 0 | 0 |
| Week 5: 2 hours | 0 | 0 | 1 | 0 | 0 |
| Week 5: 3 hours | 0 | 0 | 1 | 0 | 0 |
| Week 6: Predose | 0 | 0 | 0 | 0 | 0 |
| Week 6: 1 hour | 0 | 0 | 0 | 1 | 0 |
| Week 6: 2 hours | 0 | 0 | 0 | 1 | 0 |
| Week 6: 3 hours | 0 | 0 | 0 | 0 | 0 |
TEAEs were defined as any AE that occurred after the first administration of the study drug and until the end of the study. AEs were defined as any untoward medical occurrence in a participant administered study drug and that did not necessarily have a causal relationship with the study drug. SAEs were defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, an important medical event. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in 'Reported Adverse Events' Section.
| Participants | Cohort 1: MMC Plus Chemophase 20,000 U | Cohort 2: MMC Plus Chemophase 60,000 U | Cohort 3: MMC Plus Chemophase 200,000 U | Cohort 4: MMC Plus Chemophase 400,000 U | Cohort 5: MMC Plus Chemophase 800,000 U |
|---|---|---|---|---|---|
| TEAEs | 1 | 1 | 4 | 2 | 10 |
| SAEs | 1 | 0 | 2 | 0 | 2 |
| Participants | Cohort 1: MMC Plus Chemophase 20,000 U | Cohort 2: MMC Plus Chemophase 60,000 U | Cohort 3: MMC Plus Chemophase 200,000 U | Cohort 4: MMC Plus Chemophase 400,000 U | Cohort 5: MMC Plus Chemophase 800,000 U |
|---|---|---|---|---|---|
| Number of Participants Who Remained Tumor Free at the End of the Study | 2 | 0 | 2 | 1 | 6 |
Collected over Baseline up to 2 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: MMC Plus Chemophase 20,000 U | — | 1/3 (33.3%) | 0/3 (0%) |
| Cohort 2: MMC Plus Chemophase 60,000 U | — | 0/3 (0%) | 1/3 (33.3%) |
| Cohort 3: MMC Plus Chemophase 200,000 U | — | 2/6 (33.3%) | 4/6 (66.7%) |
| Cohort 4: MMC Plus Chemophase 400,000 U | — | 0/3 (0%) | 2/3 (66.7%) |
| Cohort 5: MMC Plus Chemophase 800,000 U | — | 2/12 (16.7%) | 10/12 (83.3%) |
| Event | Cohort 1: MMC Plus Chemophase 20,000 U | Cohort 2: MMC Plus Chemophase 60,000 U | Cohort 3: MMC Plus Chemophase 200,000 U | Cohort 4: MMC Plus Chemophase 400,000 U | Cohort 5: MMC Plus Chemophase 800,000 U |
|---|---|---|---|---|---|
| SyncopeNervous system disorders | 1/3 | 0/3 | 0/6 | 0/3 | 0/12 |
| NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 1/6 | 0/3 | 0/12 |
| Small cell lung cancer stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 1/6 | 0/3 | 0/12 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/3 | 0/3 | 1/6 | 0/3 | 0/12 |
| Chest painGeneral disorders | 0/3 | 0/3 | 1/6 | 0/3 | 0/12 |
| PneumoniaInfections and infestations | 0/3 | 0/3 | 0/6 | 0/3 | 1/12 |
| Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 0/6 | 0/3 | 1/12 |
| Acute myocardial infarctionCardiac disorders | 0/3 | 0/3 | 0/6 | 0/3 | 1/12 |
| Angina unstableCardiac disorders | 0/3 | 0/3 | 0/6 | 0/3 | 1/12 |
| Event | Cohort 1: MMC Plus Chemophase 20,000 U | Cohort 2: MMC Plus Chemophase 60,000 U | Cohort 3: MMC Plus Chemophase 200,000 U | Cohort 4: MMC Plus Chemophase 400,000 U | Cohort 5: MMC Plus Chemophase 800,000 U |
|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/3 | 1/3 | 2/6 | 0/3 | 2/12 |
| CellulitisInfections and infestations | 0/3 | 1/3 | 0/6 | 0/3 | 0/12 |
| Cerebral ischaemiaNervous system disorders | 0/3 | 1/3 | 0/6 | 0/3 | 0/12 |
| Red blood cells urine positiveInvestigations | 0/3 | 0/3 | 1/6 | 1/3 | 0/12 |
| White blood cells urine positiveInvestigations | 0/3 | 0/3 | 1/6 | 1/3 | 0/12 |
| Blood urine presentInvestigations | 0/3 | 0/3 | 0/6 | 1/3 | 0/12 |
| White blood cells urineInvestigations | 0/3 | 0/3 | 0/6 | 1/3 | 0/12 |
| Asymptomatic bacteriuriaInfections and infestations | 0/3 | 0/3 | 1/6 | 0/3 | 0/12 |
| NasopharyngitisInfections and infestations | 0/3 | 0/3 | 1/6 | 0/3 | 0/12 |
| HeadacheNervous system disorders | 0/3 | 0/3 | 1/6 | 0/3 | 0/12 |
| Age, Continuous(years) | Cohort 1: MMC Plus Chemophase 20,000 U | Cohort 2: MMC Plus Chemophase 60,000 U | Cohort 3: MMC Plus Chemophase 200,000 U | Cohort 4: MMC Plus Chemophase 400,000 U | Cohort 5: MMC Plus Chemophase 800,000 U | Total |
|---|---|---|---|---|---|---|
| Mean | 66.7 ± 11.24 | 67.0 ± 8.54 | 65.7 ± 10.33 | 73.7 ± 3.79 | 68.0 ± 10.54 | 67.9 ± 9.44 |
| Sex: Female, Male(Participants) | Cohort 1: MMC Plus Chemophase 20,000 U | Cohort 2: MMC Plus Chemophase 60,000 U | Cohort 3: MMC Plus Chemophase 200,000 U | Cohort 4: MMC Plus Chemophase 400,000 U | Cohort 5: MMC Plus Chemophase 800,000 U | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 2 | 2 | 0 | 3 | 7 |
| Male | 3 | 1 | 4 | 3 | 9 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2006 to primary completion in Aug 2009, 40 months.
Results were first posted in Oct 2021, 12 years 2 months after primary completion. A results delay was requested in Aug 2018.
Of 39 industry-sponsored phase 1/2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 74. This study's 40 months is below that.
Counting every sponsor, half of 67 studies reached it within 52 months; a quarter within 35 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mitomycin · Hyaluronidase (human recombinant)